Curaxys hires five more technologists.

Since its founding in 2009, the biotech Curaxys located in Cádiz, Spain, has hired fourteen highly qualified employees with permanent contracts through loans by Inncorpora 2010 (4 people), Inncorpora TU 2011 (2 people), Inncorpora TU 2012 (3 people) and Inncorpora FPGS 2011 (5 people).

Curaxys S.L. is a unique Spanish biotechnology company that researches, develops, manufactures and will commercialise biosimilars in one single integrated process, aimed at diseases with high incidence diseases, such as breast cancer.

The innovative company owns three unique patented technology platforms, named CuraMab ®, GreenMab® and Xpancell ®, which are focused on the production of biosimilars (monoclonal antibodies) and on Advanced Therapies to treat the diabetic foot.

The biotech, located in the Tecnobahía Technology Park, is ranked among the world top ten companies devoted to research biologics, as stated by Datamonitor Pipeline Trends (HC00149-002, December 2011).

Due to the characteristics of the technology, Curaxys has been financially supported by the Ministry of Economy and Competitiveness, Ministry of Industry and Commerce, the Junta de Andalucía (IDEA Agency) and the Centre for Industrial Technological Development (CDTI) with the following aids: Innplanta 2011, Reindustrialización 2010 and 2011, Regional Incentives, by Creating technology-based company, individual research project and different Programmes of Inncorpora.
The goal of the aid is to encourage the hiring of “High Qualified Technologists” (technologists-FPGS) and graduates (TU) by companies aimed at the development of industrial research and technological development, as well as to encourage their further formation.

Importantly, Curaxys will start its commercial activity from January 2013 on, including the launch of generic medicines to be sold through the Spanish Chemist, in order to support research activities and the innovative company.

Research Team

For further information please contact:
Paula Esteban del Río.
Communication and Marketing Department
Móvil: +34 609 834 996

More on Curaxys
We focus on the research, production and commercialization of recombinant proteins added value through the utilization of CuraMab® with specific human cell lines
Our expression system allows us to reach of recombinant protein levels that are clearly above those currently available.
We developed a downstream technological platform on the basis of our own laboratory data.

More articles

  • Curaxys obtains financing for the purchase of equipment with the help granted by Innplanta 2012
  • Curaxys hires five more technologists.
  • One of the largest biopharmaceutical projects in Europe to be started at Tecnobahía.
  • Innovaxis, a novel company for “custom medicine”
  • Strategic Alliance for cancer disease
  • UCA and Curaxys create a Cathedra in biopharmaceuticals in order to research biosimilar proteins
  • Curaxys is ranked among the world top ten companies in the research of biologic generic medicines

  • Copyright 2012 Curaxys. All Rights Reserved
    Legal Advice